In this interactive video module, expert faculty discuss safety and tolerability considerations for ART regimen selection and strategies to individualize regimen selection to reduce AEs associated with ART in persons with HIV
Review key data from AIDS 2020 and other sources informing individualized ART management to improve tolerability and minimize adverse events; topics include weight gain, cardiometabolic outcomes, and considerations for women of childbearing potential and during pregnancy.
Review data and guideline recommendations informing ART management for specific patient populations to improve tolerability and minimize adverse events and potential drug-drug interactions
Review key data from 2020 conferences, including HIV Drug Therapy Glasgow and IDWeek, on potential causes and consequences of weight gain with ART and ART safety during conception or pregnancy.
During the past 2 years, guidelines have shifted their recommendations on use of DTG around the time of conception and during pregnancy. As data and guidance evolve, which ART regimens should we recommend to PWH in these settings?
Certain INSTIs and TAF are associated with excessive weight gain in PWH. Here’s my take on what we know, what we don’t, and the need for clinical trials to assess mechanism and management strategies.
Here’s my take on what clinicians who treat HIV need to know about bone loss risk and bone health screening in our patients.
Data from 2020 conferences have shed new light on the issues of ARV-associated weight gain and ART safety during conception and pregnancy. Here are expert answers to your outstanding questions.
In this case-based, focused activity, review the latest data from 2020 scientific meetings on weight gain, cardiometabolic endpoints, and pregnancy outcomes with current ART regimens.
Listen to Brian Wood, MD, discuss the latest HIV treatment safety and tolerability data from 2020 conferences, including weight gain with ART and ART safety in pregnancy.